AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 279: H1447-H1452, 2000;
0363-6135/00 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tracey, W. R.
Right arrow Articles by Oates, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tracey, W. R.
Right arrow Articles by Oates, P. J.
Vol. 279, Issue 4, H1447-H1452, October 2000

Aldose reductase inhibition alone or combined with an adenosine A3 agonist reduces ischemic myocardial injury

W. Ross Tracey, William P. Magee, Craig A. Ellery, Joseph T. MacAndrew, Andrew H. Smith, Delvin R. Knight, and Peter J. Oates

Department of Cardiovascular and Metabolic Diseases, Pfizer, Incorporated, Groton, Connecticut 06340

This study investigated whether aldose reductase (AR) inhibition with zopolrestat, either alone or in combination with an adenosine A3-receptor agonist (CB-MECA), reduced myocardial ischemic injury in rabbit hearts subjected to 30 min of regional ischemia and 120 min of reperfusion. Zopolrestat reduced infarct size by up to 61%, both in vitro (2 nM to 1 µM; EC50 = 24 nM) and in vivo (50 mg/kg). Zopolrestat reduced myocardial sorbitol concentration (index of AR activity) by >50% (control, 15.0 ± 2.2 nmol/g; 200 nM zopolrestat, 6.7 ± 1.3 nmol/g). A modestly cardioprotective concentration of CB-MECA (0.2 nM) allowed a 50-fold reduction in zopolrestat concentration while providing a similar reduction in infarct size (infarct area/area at risk: control, 62 ± 2%; 1 µM zopolrestat, 24 ± 5%; 20 nM zopolrestat plus 0.2 nM CB-MECA, 20 ± 4%). In conclusion, AR inhibition is cardioprotective both in vitro and in vivo. Furthermore, combining zopolrestat with an A3 agonist allows a reduction in the zopolrestat concentration while maintaining an equivalent degree of cardioprotection.

cardioprotection; CB-MECA; ischemia; reperfusion; zopolrestat


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
W. R. Tracey, J. L. Treadway, W. P. Magee, J. C. Sutt, R. K. McPherson, C. B. Levy, D. E. Wilder, L. J. Yu, Y. Chen, R. M. Shanker, et al.
Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor
Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H1177 - H1184.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. R. Knight, A. H. Smith, D. M. Flynn, J. T. MacAndrew, S. S. Ellery, J. X. Kong, R. B. Marala, R. T. Wester, A. Guzman-Perez, R. J. Hill, et al.
A Novel Sodium-Hydrogen Exchanger Isoform-1 Inhibitor, Zoniporide, Reduces Ischemic Myocardial Injury in Vitro and in Vivo
J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 254 - 259.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online